🇺🇸 FDA
Pipeline program

ASP1570, ASP1570, KEYTRUDA 25 mg/mL concentrate for solution for infusion

1570-CL-0101

Phase 2 small_molecule active

Quick answer

ASP1570, ASP1570, KEYTRUDA 25 mg/mL concentrate for solution for infusion for Advanced Solid Tumors is a Phase 2 program (small_molecule) at Astellas Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Astellas Pharma GmbH
Indication
Advanced Solid Tumors
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials